Background
- Prognosis for patients with mutant isocitrate dehydrogenase (mIDH) gliomas is influenced by tumor type, size, neurologic deficits, and age.
- Traditionally, patients > 45 years old are considered high-risk, prompting consideration of early chemoradiation.
- Recent promising results with the mIDH inhibitor vorasidenib challenge traditional age-based risk stratification, sparking debate over its role in treatment decisions.
- We evaluated survival relative to age and molecular data obtained from next-generation sequencing (NGS).